Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2017-02-06
Target enrollment:
Participant gender:
Summary
Various antiangiogenic agents have a modest effect in prolonging overall survival in solid
tumours. In colorectal cancer it is clear that there are some patients in whom bevacizumab
significantly prolongs survival, but it is not effective in the majority of patients.
Biomarker studies using tumour tissue and blood have failed to define a consistent biomarker
that correlates with a beneficial effect of bevacizumab on survival. DCE-MRI can detect
changes in tumour blood flow which, in early phase drug studies, correlated with subsequent
tumour responses, but is too expensive and time consuming to be used in larger scale trials.
DCE-US is a promising biomarker for use in this group of patients with antiangiogenic agents,
as detailed above. The investigators wish to use this technique as a predictive biomarker for
any effects Aflibercept has on OS and PFS in patients with metastatic colorectal cancer
refractory to standard treatment.